{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 426, 'offsetInEndSection': 487, 'text': 'The limit of detection (LoD) and limit of quantitation (LoQ) ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36206626'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Missing values caused by the limit of detection or quantification (LOD/LOQ) were widely observed in mass spectrometry', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36308687'}, {'offsetInBeginSection': 901, 'offsetInEndSection': 984, 'text': 'Limits of detection (LOD) and quantification (LOQ) at 10 and 20\\u2009ng/g were achieved,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36239213'}, {'offsetInBeginSection': 579, 'offsetInEndSection': 759, 'text': 'The quantitative parameters of sensor for silver ion are determined as the limit of detection (LOD) 5.95\\xa0\u00d7\\xa010-7 M, and limit of quantitation (LOQ) 1.98\\xa0\u00d7\\xa010-8 M in the linear range', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36150260'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 236, 'text': 'Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21603916'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': '* Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantitation (LoQ) are terms used to describe the smallest concentration of a measurand that can be reliably measured by an analytical procedure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18852857'}, {'offsetInBeginSection': 355, 'offsetInEndSection': 512, 'text': 'The linear range of glyoxylic acid concentration is 0-0.028\\u2009M. The limits of detection (LOD) and quantitation (LOQ) are 0.0019\\u2009M and 0.00577\\u2009M, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32308686'}, {'offsetInBeginSection': 591, 'offsetInEndSection': 828, 'text': 'Results indicated that the dynamic ranges of three fur-bearing animals were all from 1% to 90%; the limit of detection (LOD) and limit of quantification (LOQ) for three fur-bearing animals were same, with LOD 0.1% (w/w) and LOQ 1% (w/w).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33799266'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8013092'}, {'offsetInBeginSection': 500, 'offsetInEndSection': 593, 'text': 'The limits of detection (LOD) and quantitation (LOQ) were 0.6 and 2.1 microg/L, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11878590'}, {'offsetInBeginSection': 364, 'offsetInEndSection': 514, 'text': 'tion is important for the analysis of aflatoxin in hazelnuts. The limit of detection (LOD) and limit of quantification (LOQ) are two important paramet', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28911409'}, {'offsetInBeginSection': 490, 'offsetInEndSection': 587, 'text': 'Limits of detection (LOD) and quantitation (LOQ) for UV detection are 1 and 2 mg/L, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21662779'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 719, 'text': 'The limit of detection (LOD) for any analytical procedure, the point at which analysis is just feasible, may be determined by a statistical approach based on measuring replicate blank (negative) samples or by an empirical approach, consisting of measuring progressively more dilute concentrations of analyte. The limit of quantitation (LOQ), or concentration at which quantitative results can be reported with a high degree of confidence, may likewise be determined by either approach. We used both methods to determine LOD and LOQ for forensic gas chromatographic-mass spectrometric (GC-MS) analyses of abused drugs. The statistically determined LOD and LOQ values for these assays underestimated the LOD because of th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8013092'}]\n                 'Are LOQ and LOD the same?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 847, 'offsetInEndSection': 1091, 'text': 'Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36227551'}, {'offsetInBeginSection': 1872, 'offsetInEndSection': 1989, 'text': 'DeepSurv models consistently outperformed CoxPH; both approaches performed best when provided with all the datasets. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33858811'}, {'offsetInBeginSection': 847, 'offsetInEndSection': 1186, 'text': 'This analysis revealed that survival analysis models outperformed binary classification models for risk assessment, and the performance of the survival analysis methods-Cox model regularized with ridge penalty (Cox-Ridge) and partial least squares (PLS) regression for Cox model (Cox-PLS)-were generally more robust than the other methods.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35358302'}, {'offsetInBeginSection': 597, 'offsetInEndSection': 946, 'text': 'Then, we demonstrate that the resulting method, referred to as ELMCoxBAR, can outperform some other state-of-art survival prediction methods such as L1 - or L2 -regularized Cox regression, random survival forest with various splitting rules, and boosted Cox model, in terms of its predictive performance using both simulated and real world datasets.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30632193'}, {'offsetInBeginSection': 751, 'offsetInEndSection': 974, 'text': 'Furthermore, machine learning approaches have been adapted for survival analysis, to fit nonlinear and complex interaction effects between predictors, and achieve more accurate prediction of individual survival probability.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31896241'}, {'offsetInBeginSection': 1192, 'offsetInEndSection': 1424, 'text': ' We review traditional survival methods and regularization methods, with various penalty functions, for the analysis of high-dimensional genomics, and describe machine learning techniques that have been adapted to survival analysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31896241'}, {'offsetInBeginSection': 665, 'offsetInEndSection': 861, 'text': \" Furthermore, although machine learning and data mining methods are based on statistics, most such techniques do not address the biologist's requirement for sound mathematical confidence measures.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12603013'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'BACKGROUND: Machine learning-based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34910160'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 390, 'text': 'BACKGROUND: Over the recent years, machine learning methods have been increasingly explored in cancer prognosis because of the appearance of improved machine learning algorithms. These algorithms can use censored data for modeling, such as support vector machines for survival analysis and random survival forest (RSF). However, it is still debated whether traditional (Cox proportional haz', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35179504'}]\n                 'Do machine learning-based methods outperform statistical methods for survival analysis?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 3172, 'offsetInEndSection': 3340, 'text': 'INTERPRETATION: Erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34800417'}]\n                 'Was erythropoietin effective for optic neuritis in the TONE trial?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 12, 'offsetInEndSection': 110, 'text': 'Omicron appears to lead to a milder illness for patients compared with previous COVID-19 variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35811082'}, {'offsetInBeginSection': 1395, 'offsetInEndSection': 1606, 'text': 'Most of those infected with Omicron experience symptoms, and the Omicron variant appears to lead to less severe disease. However, this does not mean that all the infected experience an Omicron infection as mild.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35811082'}, {'offsetInBeginSection': 1199, 'offsetInEndSection': 1302, 'text': 'In this study, symptoms of COVID-19 tended to be milder than described for previous SARS-CoV2 variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35751531'}, {'offsetInBeginSection': 1803, 'offsetInEndSection': 1952, 'text': 'These early national data suggest that omicron is associated with a two-thirds reduction in the risk of COVID-19 hospitalisation compared with delta.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35468332'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Globally, SARS CoV-2 omicron variant has led to a notable increase of COVID-19 diagnoses, although with less severe clinical manifestations and decreased hospitalizations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36417338'}, {'offsetInBeginSection': 305, 'offsetInEndSection': 512, 'text': 'One of the newest variants is Omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35408618'}, {'offsetInBeginSection': 261, 'offsetInEndSection': 586, 'text': 'Here we compared 3-day risks of emergency department (ED) visit, hospitalization, intensive care unit (ICU) admission, and mechanical ventilation in patients who were first infected during a time period when the Omicron variant was emerging to those in patients who were first infected when the Delta variant was predominant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35018384'}, {'offsetInBeginSection': 2651, 'offsetInEndSection': 2870, 'text': 'First time SARS-CoV-2 infections occurring at a time when the Omicron variant was rapidly spreading were associated with significantly less severe outcomes than first-time infections when the Delta variant predominated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35018384'}, {'offsetInBeginSection': 1670, 'offsetInEndSection': 2194, 'text': 'After propensity-score matching for demographics, socio-economic determinants of health, comorbidities, medications and vaccination status, the 3-day risks in the Emergent Omicron cohort outcomes were consistently less than half those in the Delta cohort: ED visit: 4.55% vs. 15.22% (risk ratio or RR: 0.30, 95% CI: 0.28-0.33); hospitalization: 1.75% vs. 3.95% (RR: 0.44, 95% CI: 0.38-0.52]); ICU admission: 0.26% vs. 0.78% (RR: 0.33, 95% CI:0.23-0.48); mechanical ventilation: 0.07% vs. 0.43% (RR: 0.16, 95% CI: 0.08-0.32).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35018384'}, {'offsetInBeginSection': 389, 'offsetInEndSection': 534, 'text': 'The Omicron is highly transmissible and is spreading faster than any previous variant, but may cause less severe symptoms than previous variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35071500'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 405, 'text': 'The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity of infection than that of the delta variant (B.1.617.2). We aimed to better characterise omicron severity relative to delta by assessing the relative risk of hospital attendance, hospital admission, or death in a large national cohort.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35305296'}, {'offsetInBeginSection': 1294, 'offsetInEndSection': 1555, 'text': 'The adjusted hazard ratio (HR) of hospital attendance (not necessarily resulting in admission) with omicron compared with delta was 0\u00b756 (95% CI 0\u00b754-0\u00b758); for hospital admission and death, HR estimates were 0\u00b741 (0\u00b739-0\u00b743) and 0\u00b731 (0\u00b726-0\u00b737), respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35305296'}, {'offsetInBeginSection': 2756, 'offsetInEndSection': 2951, 'text': ' The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35305296'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 222, 'text': 'The Omicron variant (B.1.1.529) is estimated to be more transmissible than previous strains of SARS-CoV-2 especially among children, potentially resulting in croup which is a characteristic disease in children.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36419108'}, {'offsetInBeginSection': 1252, 'offsetInEndSection': 1802, 'text': 'A significant difference between the age-specific susceptibility to the Omicron and that to the pre-Omicron variants was found in the younger age group. The rise in susceptibility to the Omicron/pre-Delta variant was highest in the 10-15 years age group (5.28 times [95% CI, 4.94-5.60]), and the rise in susceptibility to the Omicron/Delta variant was highest in the 15-19 years age group (3.21 times [95% CI, 3.12-3.31]), whereas in those aged 50 years or more, the susceptibility to the Omicron/pre-Omicron remained stable at approximately twofold.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36419108'}, {'offsetInBeginSection': 1815, 'offsetInEndSection': 2023, 'text': 'Even after adjusting for contact pattern, vaccination status, and waning of vaccine effectiveness, the Omicron variant of SARS-CoV-2 tends to propagate more easily among children than the pre-Omicron strains.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36419108'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'Infection with SARS-CoV-2 variant Omicron is considered to be less severe than infection with variant Delta, with rarer occurrence of severe disease requiring intensive care.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36224216'}, {'offsetInBeginSection': 447, 'offsetInEndSection': 691, 'text': 'We found that infections caused by the Omicron variant caused significantly less morbidity, including admission to the hospital and requirement for oxygen supplementation, and significantly less mortality than those caused by the Delta variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35415869'}, {'offsetInBeginSection': 76, 'offsetInEndSection': 201, 'text': ' Early work suggests that infections caused by the Omicron variant may be less severe than those caused by the Delta variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35415869'}, {'offsetInBeginSection': 388, 'offsetInEndSection': 534, 'text': ' The Omicron is highly transmissible and is spreading faster than any previous variant, but may cause less severe symptoms than previous variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35071500'}, {'offsetInBeginSection': 372, 'offsetInEndSection': 591, 'text': ' Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36285226'}, {'offsetInBeginSection': 782, 'offsetInEndSection': 913, 'text': 'However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583528'}, {'offsetInBeginSection': 15, 'offsetInEndSection': 175, 'text': 'Severe acute respiratory syndrome coronavirus 2 infection from the Omicron variant in children/adolescents is less severe than infection from the Delta variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35404391'}, {'offsetInBeginSection': 1512, 'offsetInEndSection': 1629, 'text': 'Omicron variant infection is associated with significantly lower severity of disease compared with the Delta variant.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35788085'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 146, 'text': 'In the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35869843'}]\n                 'Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 2838, 'offsetInEndSection': 3010, 'text': 'INTERPRETATION: We do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34418398'}]\n                 'Should be used bexarotene for relapsing-remitting multiple sclerosis?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 137, 'offsetInEndSection': 1087, 'text': 'Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain. Few studies have assessed the effect of analgesics/antipyretics on vaccine immunogenicity and reactogenicity. Some studies revealed changes in certain immune response parameters post-vaccination when analgesics/antipyretics were used either prophylactically or therapeutically. Still, there is no evidence that these changes impact vaccine efficacy. Specific data on the impact of analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines are limited. However, available data from clinical trials of licensed vaccines, along with recommendations from public health bodies around the world, should provide reassurance to both healthcare professionals and vaccine recipients that short-term use of analgesics/antipyretics at non-prescription doses is unlikely to affect vaccine-induced immunity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 342, 'text': ' Although fever is part of the normal inflammatory process after immunisation, prophylactic antipyretic drugs are sometimes recommended to allay concerns of high fever and febrile convulsion. We assessed the effect of prophylactic administration of paracetamol at vaccination on infant febrile reaction rates and vaccine responses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19837254'}, {'offsetInBeginSection': 2515, 'offsetInEndSection': 2746, 'text': ' Although febrile reactions significantly decreased, prophylactic administration of antipyretic drugs at the time of vaccination should not be routinely recommended since antibody responses to several vaccine antigens were reduced.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19837254'}, {'offsetInBeginSection': 2023, 'offsetInEndSection': 2341, 'text': 'Antibody geometric mean concentrations (GMCs) were significantly lower in the prophylactic paracetamol group than in the no prophylactic paracetamol group after primary vaccination for all ten pneumococcal vaccine serotypes, protein D, antipolyribosyl-ribitol phosphate, antidiphtheria, antitetanus, and antipertactin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19837254'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 238, 'text': 'Worldwide, paracetamol is administered as a remedy for complaints that occur after vaccination. Recently published results indicate that paracetamol inhibits the vaccination response in infants when given prior to vaccination.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24897504'}, {'offsetInBeginSection': 980, 'offsetInEndSection': 1699, 'text': 'One month after the second booster vaccination, the anti-HBs level in the prophylactic paracetamol group was significantly lower (p = 0.048) than the level in the control group (4257 mIU/mL vs. 5768 mIU/mL). The anti-HBs level in the therapeutic paracetamol group (4958 mIU/mL) was not different (p = 0.34) from the level in the control group. Only prophylactic paracetamol treatment, and not therapeutic treatment, during vaccination has a negative influence on the antibody concentration after hepatitis B vaccination in adults. These findings prompt to consider therapeutic instead of prophylactic treatment to ensure maximal vaccination efficacy and retain the possibility to treat pain and fever after vaccination.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24897504'}, {'offsetInBeginSection': 137, 'offsetInEndSection': 278, 'text': 'Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}, {'offsetInBeginSection': 389, 'offsetInEndSection': 556, 'text': 'Some studies revealed changes in certain immune response parameters post-vaccination when analgesics/antipyretics were used either prophylactically or therapeutically.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'While antipyretic analgesics are widely used to ameliorate vaccine adverse reactions, their use has been associated with blunted vaccine immune responses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27246296'}, {'offsetInBeginSection': 746, 'offsetInEndSection': 1087, 'text': 'However, available data from clinical trials of licensed vaccines, along with recommendations from public health bodies around the world, should provide reassurance to both healthcare professionals and vaccine recipients that short-term use of analgesics/antipyretics at non-prescription doses is unlikely to affect vaccine-induced immunity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}, {'offsetInBeginSection': 629, 'offsetInEndSection': 745, 'text': 'Specific data on the impact of analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines are limited.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}, {'offsetInBeginSection': 136, 'offsetInEndSection': 278, 'text': ' Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}, {'offsetInBeginSection': 388, 'offsetInEndSection': 556, 'text': ' Some studies revealed changes in certain immune response parameters post-vaccination when analgesics/antipyretics were used either prophylactically or therapeutically.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}, {'offsetInBeginSection': 628, 'offsetInEndSection': 745, 'text': ' Specific data on the impact of analgesic/antipyretic medications on immunogenicity of COVID-19 vaccines are limited.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842'}]\n                 'Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 0, 'offsetInEndSection': 268, 'text': 'Lumasiran (Oxlumo\u2122) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33405070'}, {'offsetInBeginSection': 326, 'offsetInEndSection': 388, 'text': 'OXLUMO (lumasiran) for the treatment of primary hyperoxaluria,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34154993'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 506, 'text': 'Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to N-acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, and with the recent approvals of GIVLAARI (givosiran) for the treatment of acute hepatic porphyria, OXLUMO (lumasiran) for the treatment of primary hyperoxaluria, and Leqvio (inclisiran) for the treatment of hypercholesterolemia, the technology has been well validated clinically.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34154993'}, {'offsetInBeginSection': 901, 'offsetInEndSection': 1240, 'text': 'In this context we discuss nedosiran (Dicerna Pharmaceuticals, Inc.) and lumasiran (Alnylam Pharmaceuticals), which are both novel RNAi therapies for primary hyperoxaluria that selectively reduce hepatic expression of lactate dehydrogenase and glycolate oxidase respectively, reducing hepatic oxalate production and urinary oxalate levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34022071'}, {'offsetInBeginSection': 622, 'offsetInEndSection': 737, 'text': 'On 23 November 2020, lumasiran was approved in the USA for the treatment of adult and paediatric patients with PH1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33405070'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 64, 'text': 'Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33789010'}, {'offsetInBeginSection': 502, 'offsetInEndSection': 621, 'text': 'On 19 November 2020, lumasiran received its first global approval in the EU for the treatment of PH1 in all age groups.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33405070'}, {'offsetInBeginSection': 507, 'offsetInEndSection': 712, 'text': 'Efforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a siRNA product against glycolate oxidase, which has become the first effective therapy to treat PH1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33513899'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34906487'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 246, 'text': 'Several new drugs have been approved to treat rare genetic disorders: setmelanotide for certain conditions causing obesity; lumasiran for primary hyperoxaluria type 1, a kidney disorder; and lonafarnib for two diseases that cause premature aging.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33497125'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 97, 'text': 'Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35747094'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 82, 'text': 'The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35015123'}, {'offsetInBeginSection': 956, 'offsetInEndSection': 1079, 'text': ' Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35731461'}, {'offsetInBeginSection': 1919, 'offsetInEndSection': 2084, 'text': 'SIONS: Lumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels.CLINI', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33985991'}, {'offsetInBeginSection': 315, 'offsetInEndSection': 472, 'text': 'Lumasiran is an RNA interference (RNAi) therapeutic agent that reduces hepatic oxalate production, which has been recently approved for the treatment of PH1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35237473'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 291, 'text': 'RATIONALE & OBJECTIVE: Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with PH1 and a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35843439'}]\n                 'Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 774, 'offsetInEndSection': 1015, 'text': 'International recommendations suggest maintaining asthma under control to limit exacerbations occurrence, by using all available treatment. The minimum steroid dosage effective to control symptoms should be maintained to avoid exacerbations;', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33297799'}, {'offsetInBeginSection': 725, 'offsetInEndSection': 1332, 'text': 'The meta-analysis revealed no significant difference in the risk for the development of a fatal course of COVID-19 with preadmission use of inhaled corticosteroids in patients with COVID-19 relative to non-use of inhaled corticosteroids (pooled odds ratio=1.28; 95% confidence interval 0.73-2.26). Similarly, the meta-analysis observed no significant difference in the risk for the development of a severe course of COVID-19 with preadmission use of inhaled corticosteroids in patients with COVID-19 relative to non-use of inhaled corticosteroids (pooled odds ratio=1.45; 95% confidence interval 0.96-2.20).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33461348'}, {'offsetInBeginSection': 1345, 'offsetInEndSection': 1450, 'text': 'Our findings assured the safety of continued use of inhaled corticosteroids during the COVID-19 pandemic.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33461348'}, {'offsetInBeginSection': 1558, 'offsetInEndSection': 1781, 'text': 'Our study showed that asthma is not associated with worse outcomes of COVID-19, despite the higher need for respiratory support compared with the general population, while the use of ICS allowed for a shorter hospital stay.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35887681'}, {'offsetInBeginSection': 1379, 'offsetInEndSection': 1545, 'text': 'Patients with asthma in regular therapy with ICS at home had significantly shorter hospital stay compared to those with no treatments (25.2 vs. 11.3 days, p = 0.024).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35887681'}, {'offsetInBeginSection': 506, 'offsetInEndSection': 743, 'text': 'Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36450371'}, {'offsetInBeginSection': 358, 'offsetInEndSection': 479, 'text': 'The benefit-risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or COPD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32348052'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 224, 'text': 'Due to its known and important benefits ICS should be prescribed as usual for both asthma and COPD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34295392'}, {'offsetInBeginSection': 296, 'offsetInEndSection': 423, 'text': 'The available recommendations state that patients with asthma should use inhaled glucocorticosteroids (GCS) on a regular basis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35801604'}, {'offsetInBeginSection': 1648, 'offsetInEndSection': 1762, 'text': 'These findings should encourage clinicians to continue ICS therapy for COPD patients during the COVID-19 pandemic.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34081722'}, {'offsetInBeginSection': 505, 'offsetInEndSection': 743, 'text': ' Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36450371'}, {'offsetInBeginSection': 451, 'offsetInEndSection': 770, 'text': ' The available evidence suggests that severe asthma patients do not have an increased risk of poor COVID-19 outcomes and that it is safe to treat asthmatic patients with inhaled corticosteroids (ICS) and biologics during the pandemic, even though some studies indicate that high doses of ICS may predispose to COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34926333'}, {'offsetInBeginSection': 203, 'offsetInEndSection': 293, 'text': ' However, patients with asthma or COPD should continue all prescribed inhaled medications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33248363'}, {'offsetInBeginSection': 204, 'offsetInEndSection': 293, 'text': 'However, patients with asthma or COPD should continue all prescribed inhaled medications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33248363'}, {'offsetInBeginSection': 1044, 'offsetInEndSection': 1223, 'text': 'Additionally, the use of systemic or inhaled glucocorticoids does not appear to increase the risk of severe COVID-19, but there is no evidence guiding the use of biologic therapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33357281'}, {'offsetInBeginSection': 1484, 'offsetInEndSection': 1721, 'text': 'Our study supports the recommendation that patients with chronic pulmonary diseases, including asthma and COPD who require treatment with either inhaled or systemic corticosteroids, should continue their use during the COVID-19 pandemic.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33276252'}]\n                 'Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 543, 'offsetInEndSection': 890, 'text': 'In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781'}]\n                 'Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 2312, 'offsetInEndSection': 2536, 'text': \"CONCLUSIONS: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921450'}]\n                 'Is Cinpanemab effective for Parkinson\u2019s Disease?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': 'A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32093010'}, {'offsetInBeginSection': 673, 'offsetInEndSection': 791, 'text': 'The CRISPR-Cas12a system can detect both L858R and T790M with a limit of detection of 0.005% in less than three hours.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32093010'}, {'offsetInBeginSection': 1023, 'offsetInEndSection': 1249, 'text': 'The CRISPR-Cas12a system could detect L858R in plasma of two lung cancer patients whose tissue biopsies are positive for L858R, and one plasma sample of three lung cancer patients whose tissue biopsies are positive for T790M. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32093010'}, {'offsetInBeginSection': 1360, 'offsetInEndSection': 1562, 'text': ' This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32093010'}]\n                 'Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 485, 'offsetInEndSection': 1095, 'text': 'PRP-40 is particularly required for inclusion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that PRP-40 is specifically required for microexons surrounded by conventionally sized introns. Knockdown of the orthologous PRPF40A in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142'}]\n                 'Is PRP-40 involved in microexon splicing?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'Ocrelizumab (Ocrevus\u00ae) is an intravenously administered, humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35192158'}, {'offsetInBeginSection': 2194, 'offsetInEndSection': 2363, 'text': 'When using the anti-CD20 monoclonal antibodies ocrelizumab and ofatumumab in the treatment of MS, it is not necessary to test for NAbs as these occur very infrequently. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35590041'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 35, 'text': 'Ocrelizumab for multiple sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583174'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 318, 'text': 'BACKGROUND: Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in adults with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583174'}]\n                 'Is ocrelizumab effective for primary progressive multiple sclerosis?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 0, 'offsetInEndSection': 91, 'text': 'Silencing of SRRM4 suppresses microexon inclusion and promotes tumor growth across cancers.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33621242'}, {'offsetInBeginSection': 1029, 'offsetInEndSection': 1683, 'text': 'We show that this silencing is favorable for tumor growth, as decreased SRRM4 expression in tumors is correlated with an increase in mitotic gene expression, and up-regulation of SRRM4 in cancer cell lines dose-dependently inhibits proliferation in vitro and in a mouse xenograft model. Further, this proliferation inhibition is accompanied by induction of neural-like expression and splicing patterns in cancer cells, suggesting that SRRM4 expression shifts the cell state away from proliferation and toward differentiation. We therefore conclude that SRRM4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33621242'}]\n                 'Does silencing of SRRM4 inhibit tumor growth across cancers?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Daridorexant (Quviviq\u2122; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35298826'}, {'offsetInBeginSection': 466, 'offsetInEndSection': 1224, 'text': 'Daridorexant was superior to placebo in reducing wake time after sleep onset (MD\\u2009=\\u2009-13.26; 95% CI, -15.48 to -11.03; P\\u2009<\\u20090.00001), latency to persistent sleep (MD\\u2009=\\u2009-7.23; 95% CI, -9.60 to -4.85; P\\u2009<\\u20090.00001), with increasing the total sleep time (MD\\u2009=\\u200914.80; 95% CI, 11.18-18.42; P\\u2009<\\u20090.00001) and subjective total sleep time (MD\\u2009=\\u200914.80; 95% CI, 11.18-18.42], P\\u2009<\\u20090.00001). The 25 mg and 50 mg were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\\u2009=\\u20091.19; 95% CI, 1.05-1.35;, P\\u2009=\\u20090.005], specifically somnolence (RR\\u2009=\\u20091.19; 95% CI, 1.13-3.23; P\\u2009=\\u20090.005) and fatigue (RR\\u2009=\\u20092.01; 95% CI, 1.21-3.36; P\\u2009=\\u20090.007). Daridorexant is superior to placebo in improving sleep quality. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36473030'}]\n                 'Is daridorexant effective for insomnia?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 686, 'offsetInEndSection': 1214, 'text': 'POETYK PSO-1 and PSO-2 involved 1688 patients with moderate-to-severe psoriasis. After 16\\xa0weeks, in both studies, over 50% of patients treated with deucravacitinib reached PASI75, which was significantly superior to placebo and apremilast. In POETYK PSO-1, these results improved until week 24 and were maintained through week 52, with over 65% of patients achieving PASI75 at this point. A reduction in signs and symptoms was also reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35960487'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'INTRODUCTION: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35025062'}, {'offsetInBeginSection': 1500, 'offsetInEndSection': 1682, 'text': 'CONCLUSION: Deucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35025062'}, {'offsetInBeginSection': 1181, 'offsetInEndSection': 1338, 'text': 'CONCLUSION: Deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35820547'}]\n                 'Is deucravacitinib effective for psoriasis?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 566, 'offsetInEndSection': 817, 'text': 'Here, we show that the expression of the H3K9 demethylase IBM1 (increase in BONSAI methylation 1) requires DNA methylation. Surprisingly, the regulatory methylated region is contained in an unusually large intron that is conserved in IBM1 orthologues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22580822'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'DNA methylation in an intron of the IBM1 histone demethylase gene stabilizes chromatin modification patterns.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22580822'}, {'offsetInBeginSection': 515, 'offsetInEndSection': 780, 'text': 'Polyadenylation (poly(A) sequencing reveals that AAE complex has a substantial influence on poly(A) site usage of heterochromatin-containing genes, including not only intronic heterochromatin-containing genes but also the genes showing overlap with heterochromatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33438356'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'Heterochromatin is widespread in eukaryotic genomes and has diverse impacts depending on its genomic context.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33438356'}, {'offsetInBeginSection': 1050, 'offsetInEndSection': 1215, 'text': 'Combining methylation data with mRNA sequencing revealed that DNA methylation in promoters, introns and exons may have different roles in regulating gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33506534'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 200, 'text': 'In several eukaryotic organisms, heterochromatin (HC) in the introns of genes can regulate RNA processing, including polyadenylation, but the mechanism underlying this regulation is poorly understood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28808009'}, {'offsetInBeginSection': 494, 'offsetInEndSection': 1092, 'text': 'Here we report that ASI1 and EDM2 form a protein complex in vivo via a bridge protein, ASI1-Immunoprecipitated Protein 1 (AIPP1), which is another RNA recognition motif-containing protein. The complex also may contain the Pol II CTD phosphatase CPL2, the plant homeodomain-containing protein AIPP2, and another BAH domain protein, AIPP3. As is the case with dysfunction of ASI1 and EDM2, dysfunction of AIPP1 impedes the use of distal polyadenylation sites at tested intronic HC-containing genes, such as the histone demethylase gene IBM1, resulting in a lack of functional full-length transcripts.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28808009'}, {'offsetInBeginSection': 680, 'offsetInEndSection': 911, 'text': 'Interestingly, hypomethylation of introns is correlated with higher levels of intron expression in mRNA and the methylation level of an intron is inversely correlated with its retention in mRNA from the gene in which it is located.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29330282'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 214, 'text': 'Regulation of gene expression by DNA methylation in gene promoter regions is well studied; however, the effects of methylation in the gene body (exons and introns) on gene expression are comparatively understudied.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29330282'}, {'offsetInBeginSection': 425, 'offsetInEndSection': 624, 'text': 'Consistent with previous work we found that intragenic methylation is positively correlated with gene expression and that exons are more highly methylated than their neighboring intronic environment.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25765649'}]\n                 'Can the epigenetic status of introns affect gene expression?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 124, 'offsetInEndSection': 252, 'text': 'Bioluminescence-optogenetics is mediated by luminopsin fusion proteins-light-sensing opsins fused to light-emitting luciferases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33398820'}, {'offsetInBeginSection': 238, 'offsetInEndSection': 466, 'text': 'Here we have expanded and refined the versatility of luminopsin tools by fusing an alternative luciferase variant with high light emission, Gaussia luciferase mutant GLucM23, to depolarizing and hyperpolarizing channelrhodopsins', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28862809'}, {'offsetInBeginSection': 633, 'offsetInEndSection': 710, 'text': ' luminopsins by fusing light-sensing opsins with light-emitting luciferases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30957296'}, {'offsetInBeginSection': 343, 'offsetInEndSection': 550, 'text': 'ouse iPS-NPCs were transduced with a novel optochemogenetics fusion protein, luminopsin 3 (LMO3), which consisted of a bioluminescent luciferase, Gaussia luciferase, and an opsin, Volvox Channelrhodopsin 1. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31263065'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 235, 'text': 'Luminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26733686'}]\n                 'Are Luminopsins a fusion proteins of luminol and Rhodopsin ?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 271, 'offsetInEndSection': 574, 'text': ' Unfortunately, COVID-19 patients have symptoms similar to other common illnesses. Here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish COVID-19 from other respiratory diseases, yet such essential information is largely unavailable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32903584'}, {'offsetInBeginSection': 1275, 'offsetInEndSection': 1382, 'text': 'No symptoms are characteristic of a single infectious agent, with flu-like disorders being the most common.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36119462'}, {'offsetInBeginSection': 1227, 'offsetInEndSection': 1563, 'text': 'We show that although COVID-19 and influenza are different in many ways, there are numerous similarities; thus, in addition to using nucleic acid-based polymerase chain reaction (PCR) and antibody-based approaches, clinicians and epidemiologists should distinguish between the two using their respective characteristics in early stages.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33615750'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 210, 'text': 'An understanding of differences in clinical phenotypes and outcomes COVID-19 compared with other respiratory viral infections is important to optimise the management of patients and plan healthcare.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34226206'}, {'offsetInBeginSection': 1600, 'offsetInEndSection': 1859, 'text': 'SARS-CoV-2 is associated with more severe outcomes compared with other respiratory viruses, and although associated with specific patient and clinical characteristics at admission, a substantial overlap precludes discrimination based on these characteristics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34226206'}, {'offsetInBeginSection': 272, 'offsetInEndSection': 353, 'text': 'Unfortunately, COVID-19 patients have symptoms similar to other common illnesses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32903584'}, {'offsetInBeginSection': 168, 'offsetInEndSection': 284, 'text': 'Clinical presentation of COVID-19, however, can be difficult to distinguish from other respiratory viral infections.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32881022'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'It is difficult to distinguish coronavirus disease-2019 (COVID-19) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33135801'}, {'offsetInBeginSection': 224, 'offsetInEndSection': 370, 'text': 'Although COVID-19 has been extensively characterized clinically, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33995342'}, {'offsetInBeginSection': 297, 'offsetInEndSection': 546, 'text': ' Since the symptoms are similar to other respiratory infections, differential diagnosis in travellers arriving from countries with wide-spread COVID-19 must include other more common infections such as influenza and other respiratory tract diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32127123'}, {'offsetInBeginSection': 167, 'offsetInEndSection': 284, 'text': ' Clinical presentation of COVID-19, however, can be difficult to distinguish from other respiratory viral infections.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32881022'}, {'offsetInBeginSection': 1491, 'offsetInEndSection': 1576, 'text': 'COVID-19 and flu are two respiratory illnesses which share similar clinical symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35412847'}, {'offsetInBeginSection': 700, 'offsetInEndSection': 881, 'text': 'During influenza season, differentiating other causes of respiratory illness from COVID-19 is difficult, because common clinical manifestations of COVID-19 mimic those of influenza.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34484383'}]\n                 'Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 175, 'offsetInEndSection': 582, 'text': 'Previously dismissed as \"junk DNA\", it is the non-coding regions of the genome that are responsible for regulation, facilitating complex temporal and spatial gene expression through the combinatorial effect of numerous mechanisms and interactions working together to fine-tune gene expression. The major regions involved in regulation of a particular gene are the 5\\' and 3\\' untranslated regions and introns.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22538991'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 141, 'text': \"Post-transcriptional regulation, via 5'-UTRs (5'-untranslated regions), plays an important role in the control of eukaryotic gene expression.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18631145'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 320, 'text': \"Eukaryotic gene expression is precisely regulated at all points between transcription and translation. In this review, we focus on translational control mediated by the 3'-untranslated regions (UTRs) of mRNAs. mRNA 3'-UTRs contain cis-acting elements that function in the regulation of protein translation or mRNA decay.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28287067'}, {'offsetInBeginSection': 123, 'offsetInEndSection': 378, 'text': \"Now, we are beginning to better appreciate the role of 3'-UTR (untranslated region) cis-elements which harbor not only microRNA but also RNA-binding protein (RBP) binding sites that have significant effect on the stability and translational rate of mRNAs.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27208003'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': \"Many studies using reporter assays have demonstrated that 3' untranslated regions (3'-UTRs) regulate gene expression by controlling mRNA stability and translation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28985357'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 123, 'text': 'The untranslated regions of mRNAs can determine gene expression by influencing mRNA stability and translational efficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16430990'}, {'offsetInBeginSection': 449, 'offsetInEndSection': 623, 'text': 'In higher eukaryotes, untranslated regions (UTRs) of transcripts are one of the crucial regulators of gene expression (influencing mRNA stability and translation efficiency).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28229978'}, {'offsetInBeginSection': 821, 'offsetInEndSection': 1063, 'text': \"Our results suggest that 3'UTR sequences can function not only in cis to regulate protein expression, but also intrinsically and independently in trans, likely as noncoding RNAs, a conclusion supported by a number of previous genetic studies.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21075793'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': \"The 3' untranslated regions (3'UTRs) of eukaryotic genes regulate mRNA stability, localization and translation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21075793'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 272, 'text': \"The 5' and 3' untranslated regions of eukaryotic mRNAs (UTRs) play crucial roles in the post-transcriptional regulation of gene expression through the modulation of nucleo-cytoplasmic mRNA transport, translation efficiency, subcellular localization, and message stability.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36399486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 120, 'text': \"3' untranslated regions (UTRs) are known to play an important role in posttranscriptional regulation of gene expression.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24067953'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': \"The 3' untranslated region (3' UTR) can control gene expression by affecting the localization, stability and translation of mRNAs.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7662369'}, {'offsetInBeginSection': 448, 'offsetInEndSection': 623, 'text': ' In higher eukaryotes, untranslated regions (UTRs) of transcripts are one of the crucial regulators of gene expression (influencing mRNA stability and translation efficiency).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28229978'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 105, 'text': 'Untranslated regions (UTR) play important roles in the posttranscriptional regulation of mRNA processing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10977083'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 87, 'text': 'Untranslated gene regions (UTRs) play an important role in controlling gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34287278'}, {'offsetInBeginSection': 120, 'offsetInEndSection': 197, 'text': ' The untranslated regions (UTRs) of mRNA are hotspots for regulatory control.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28867199'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'Untranslated regions (UTRs) in eukaryotes play a significant role in the regulation of translation and mRNA half-life, as well as interacting with specific RNA-binding proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22846368'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 249, 'text': 'Untranslated regions (UTRs) of eukaryotic mRNAs play crucial roles in post-transcriptional regulation of gene expression via the modulation of nucleocytoplasmic mRNA transport, translation efficiency, subcellular localization, and message stability.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20720301'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 364, 'text': \"The 5' and 3' untranslated regions (UTRs) regulate crucial aspects of post-transcriptional gene regulation that are necessary for the maintenance of cellular homeostasis. When these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30961831'}]\n                 'Can untranslated regions (UTRs) regulate gene expression?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 730, 'offsetInEndSection': 919, 'text': 'We identified >200 significant alternative splicing (AS) events and distinct AS profiles were observed in the right (RV) and left (LV) ventricles in PLN-R14del compared to WT mouse hearts. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36375644'}, {'offsetInBeginSection': 1452, 'offsetInEndSection': 1610, 'text': 'Our findings suggest that aberrant splicing may affect Ca2+-homeostasis in the heart, contributing to the increased risk of arrythmogenesis in PLN-R14del ACM.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36375644'}]\n                 'Is alternative splicing associated with heart disease?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 680, 'offsetInEndSection': 932, 'text': 'There were no statistically significant differences between intepirdine and placebo groups (adjusted mean [95% confidence interval]) on the co-primary endpoints ADAS-Cog (-0.36 [-0.95, 0.22], P\\xa0=\\xa00.2249) and ADCS-ADL (-0.09 [-0.90, 0.72], P\\xa0=\\xa00.8260). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34095437'}, {'offsetInBeginSection': 1003, 'offsetInEndSection': 1199, 'text': 'Discussion: Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate AD dementia patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34095437'}, {'offsetInBeginSection': 871, 'offsetInEndSection': 1100, 'text': 'EXPERT OPINION: Despite early positive findings, larger phase-III trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29848076'}]\n                 'Should Intepirdine be used for Alzheimer's disease?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "no"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 783, 'offsetInEndSection': 1150, 'text': ' Concerning acute recurrent pericarditis (RP), an innovative interaction between cardiologists, internists and pediatric rheumatologists led to the intuition of a pivotal role of IL-1 in recurrent pericarditis characterized by an evident inflammatory recurrent phenotype, and recent data have shown the striking efficacy of anakinra and rilonacept in these patients. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34556390'}, {'offsetInBeginSection': 669, 'offsetInEndSection': 1258, 'text': 'Pericarditis is regarded as a stereotypical response to an acute damage of the mesothelial cells of the pericardial layers. NLRP3 inflammasome, a macromolecular structure sensing damage and releasing pro-inflammatory cytokines, is centrally involved as it releases interleukin (IL)-1\u03b2, whose auto-induction feeds an autoinflammatory disease, mostly responsible for recurrences. Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34599390'}, {'offsetInBeginSection': 810, 'offsetInEndSection': 1069, 'text': 'Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is still paucity of data regarding the use of canakinumab in the treatment of patients with RP. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34569270'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 66, 'text': 'Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459270'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 138, 'text': 'OBJECTIVE: To review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis (RP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459270'}, {'offsetInBeginSection': 1552, 'offsetInEndSection': 1763, 'text': 'CONCLUSION: Rilonacept is a safe, once weekly, subcutaneously administered IL-1 \"trap,\" indicated for the treatment of RP, and reduction in risk of recurrent pericarditis in adults and children \u226512 years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459270'}, {'offsetInBeginSection': 394, 'offsetInEndSection': 835, 'text': \"Overproduction of both IL-1\u03b1 (released by inflamed/damaged pericardial cells) and IL-1\u03b2 (released by inflammatory cells) is now a well-recognized therapeutic target in patients with recurrent idiopathic pericarditis. Currently, there are three available anti-IL-1 agents: anakinra (recombinant human IL-1Ra), rilonacept (a soluble decoy receptor 'trap', binding both IL-1\u03b1 and IL-1\u03b2), and canakinumab (human monoclonal anti-IL-1\u03b2 antibody). \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34528670'}]\n                 'Is rilonacept effective for pericarditis?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": "[{'offsetInBeginSection': 0, 'offsetInEndSection': 240, 'text': 'Tebentafusp (tebentafusp-tebn; Kimmtrak\u00ae) is a first-in-class, bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor (TCR) CD3 T cell engager being developed by Immunocore for the treatment of uveal melanoma and malignant melanoma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35364798'}, {'offsetInBeginSection': 1018, 'offsetInEndSection': 1168, 'text': 'This article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35364798'}, {'offsetInBeginSection': 265, 'offsetInEndSection': 425, 'text': 'Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35364557'}, {'offsetInBeginSection': 1757, 'offsetInEndSection': 2188, 'text': \"In a large meta-analysis, surgical treatment was associated with 6 months longer median overall survival as compared to conventional chemotherapy and, recently, tebentafusp as first-line treatment at the first interim analysis of a randomized phase III trial likewise provided a 6 months longer median overall survival compared to investigator's choice, mostly pembrolizumab; these treatments currently apply to selected patients. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34999237'}]\n                 'Is tebentafusp effective for uveal melanoma?'. \n                 You *must answer* only with lowercase 'yes' or 'no' even if you are not sure about the answer."}, {"role": "assistant", "content": "yes"}]}
